Lung cancer: a cost and outcome study based on physician practice patterns

Area of Science:

• Medical Oncology
• Health Economics
• Cancer Treatment

Background:

• Chemotherapy is an established treatment for select non-small cell lung cancer (NSCLC) patients.
• Variations in cytotoxic and supportive care drug use present opportunities to evaluate treatment approaches.
• Assessing treatment patterns, costs, and survival is crucial for optimizing cancer care.

Purpose of the Study:

• To evaluate variations in chemotherapy treatment patterns among Medical Oncologists in a large community-based private practice.
• To analyze the cost implications and survival outcomes associated with these differing practice patterns.
• To identify potential areas for cost-minimization and improved disease management in NSCLC treatment.

Main Methods:

• Retrospective review of billing data for 1215 new lung cancer patients diagnosed in 1996.
• Evaluation of chemotherapy charges, hospice care, and survival for 858 patients receiving chemotherapy.
• Comparison of practice patterns, costs, and survival between high-charge and low-charge physicians.

Main Results:

• Significant differences in practice patterns were observed among Medical Oncologists.
• Higher charges correlated with more chemotherapy cycles, increased use of second- and third-line therapies, and greater use of supportive drugs (G-CSF, erythropoietin).
• No significant difference in survival or hospice utilization was found between high- and low-charge physician groups, even for stage IV NSCLC.

Conclusions:

• Chemotherapy costs for lung cancer can vary by as much as 100% due to practice pattern differences alone, without affecting survival.
• These findings suggest that cost-minimization strategies and refined disease management approaches are feasible.
• Recent clinical data and guideline development support these suggestions for optimizing cancer care delivery.